Bioventus intentionally abuses Medicare’s resources by not reporting ASP

Discussion in 'Bioventus' started by anonymous, Jan 13, 2019 at 4:33 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    "Pharmaceutical companies also have been found to violate the False Claims Act by “marketing the spread” between an artificially high average wholesale price used by Medicare and others to determine reimbursement of the cost of the drug, and the deeply discounted prices paid by providers for the drug (“the discounted price”). The difference between the average wholesale price and the discounted price to physicians – known as the “spread” – is pure profit to the physician’s practice. The greater the spread, the more profit the hospital or physician makes, and the greater their incentive to buy drugs from that manufacturer. Marketing the spread violates the False Claims Act because the physician or hospital seeks reimbursement from Medicaid or Medicare at the falsely inflated price that the pharmaceutical company provided to the government."

    No other reason to not report ASP. None at all. If it's being used to rebate private insurers off the back of overcharging Medicare, there is evidence being passed. Inspector General is thrilled.


    https://www.hhs.gov/answers/fraud/how-do-i-report-medicare-fraud/index.html

    https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/fraud_and_abuse.pdf
     

  2. anonymous

    anonymous Guest

    Sadly Bioventus and board will blame sales and management for heat when they took it upon themselves to engage a risky endeavor
     
  3. anonymous

    anonymous Guest

    Leave our site troll. Grow up and spend time on your own companies site. If unemployed, advice - get off CP and look for jobs.
     
  4. anonymous

    anonymous Guest

    Spot on. The house will soon collapse
     
  5. anonymous

    anonymous Guest

    Sounds like Euflexxa rep is back
     
  6. anonymous

    anonymous Guest

    Sometimes you kick. Sometimes you get kicked. AJ
     
  7. anonymous

    anonymous Guest

    Aren’t all HA companies doing this now??
     
  8. anonymous

    anonymous Guest

    No one does this
     
  9. anonymous

    anonymous Guest

    That’s exactly what BioV is doing. And others that followed suit. No clinical reason to use Gelsyn over any other product. Purely a spread sale.
     
  10. anonymous

    anonymous Guest

    good Product, healthy reimbursement, good company decision!
     
  11. anonymous

    anonymous Guest

    The doctor asks, “how much is your product per syringe?” You say “it’s $x.”. He then asks , “ how much does Medicare reimburse?” And you tell him the current reimbursement amount. Nothing wrong with that exchange. No smoking gun, get over it.
     
  12. anonymous

    anonymous Guest

    Keep telling yourself that.
     
  13. anonymous

    anonymous Guest

    What's wrong with that? There really is nothing wrong with that from what I can tell...it's not like it's hard math. I stay away from discussing competitive pricing because that's where the problem lies.
     
  14. anonymous

    anonymous Guest

    NO SHIT
     
  15. anonymous

    anonymous Guest

    guess what? all HA injections are more or less the same. You can tweak math and studies, but that is the truth. providers are savvy enough to calculate the difference between their cost and insurance reimbursement.
     
  16. anonymous

    anonymous Guest

    We make it easier for accounts to maximize their spread by providing a quarterly breakdown of all costs and reimbursement rates. Save your customers the trouble and calculate the spread for them.
     
  17. anonymous

    anonymous Guest

     
  18. anonymous

    anonymous Guest

    Also known as selling on the spread.